Any feedback?
Literature summary for 3.4.14.5 extracted from
- Discovery of JANUVIATM (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes (2007), Curr. Top. Med. Chem., 7, 557-568.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | sitagliptin is a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| sitagliptin | highly selective DPP-4 inhibitor for the treatment of type 2 diabetes | Homo sapiens |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| dipeptidyl peptidase IV | - |
Homo sapiens |
| DPP-4 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
